No plan yet to revise Covishield 84-day dose gap, clarifies govt

Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports

Covishield, Covid-19 vaccine
ANI New Delhi
1 min read Last Updated : Aug 26 2021 | 8:26 PM IST
There is no proposal in consideration to change the dose interval between two Covid-19 vaccines--Covishield, Covaxin, and Sputnik V in India, National Technical Advisory Group on Immunisation's (NTAGI) chairman Dr Nk Arora said on Thursday.

Arora while speaking to ANI said, "There are several studies and programmatic data collection processes are on to assess the vaccine effectiveness. NTAGI is reviewing the vaccine effectiveness data on regular basis. Currently, there is no proposal for change in the interval of doses for COVISHIELD, COVAXIN, and SPUTNIK V under consideration."

Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports.

At present, Covishield is being administered in the country with the two doses having a gap of 12-16 weeks.

In the month of MAY this year, the gap was increased from 6-8 weeks to 12-16 weeks.When the nationwide vaccination has started in January this year, the Covishield dosage gap was set at 4-6 weeks.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineAstraZenecaSerum Institute of India

Next Story